Scoop has an Ethical Paywall
A New Drug For Diabetes Complications Trials
A New Drug For Diabetes Complications Trials
PROTEMIX CORPORATION LTD ANNOUNCES THE COMMENCEMENT OF PHASE II TRIALS OF A NEW DRUG FOR DIABETES COMPLICATIONS.
Protemix Corporation Limited today announced it had started a 12 month Phase II clinical trials programme for drug candidate GC811007. The first trial targets the reversal and prevention of cardiomyopathy in patients with Type 2 diabetes. Concurrent Phase II trials of GC811007 will target safety, pharmacology and diabetic nephropathy
Diabetes afflicts around 140 million people worldwide. The disease is associated with long term complications that affect almost every part of the body. More than 50% of patients with Type 2 diabetes die from the effects of cardiovascular disease. Modern drugs and technology have failed to suppress the progression of diabetes and diabetic complications.
Protemix Corporation Ltd is a New Zealand company dedicated to the discovery and development of novel treatments for diabetes.
ENDS
Asia Pacific AML: NZ’s Financial Crime Gap - Beyond The 'Number 8 Wire' Mentality
Westpac New Zealand: Kiwi Households Adapting Despite Widespread Cost Pressure Concerns, Westpac Survey Shows
University of Auckland: Kids’ Screen Use Linked To Long-Term Deficits In Self-Control And Attention
University of Auckland: Research To Address Equity In STEM For Māori, Pacific And Female Students
Stats NZ: Economic Impacts On New Zealand From Conflict In The Middle East – Report
Advertising Standards Authority: ASA Annual Report 2025 - Platform-Neutral Regulation Keeps Pace With Digital Advertising
